TipRanks
Go Ultimate55% OFF

Kevin D. Freeman Insider Profile

4 Followers

Kevin D. Freeman, Director at Galectin Therapeutics, holds 137.27K shares in Galectin Therapeutics (Ticker: GALT). Most recently, Kevin D. Freeman Bought 5,500 shares of Galectin Therapeutics on Dec 23, 2025 for an estimated value of $19.47K.

Kevin D. Freeman's Trading History

GALT
Galectin Therapeutics
Dec 23, 2025DirectorInformative Buy19.47K$455.73K
GALT
Insider Shares: 137.27K (0.21%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Dec 23, 2025Informative Buy$19.47K5,500$3.54-16.70%
Jul 18, 2025Informative Buy$14.45K5,000$2.89+49.10%
Dec 26, 2024Informative Buy$8.10K10,000$0.81+365.50%
Oct 17, 2024Informative Buy$3.43K1,300$2.64+87.50%
Oct 16, 2024Informative Buy$27.00K10,000$2.70+92.00%

You May Also Like

Kevin D. Freeman insider profile FAQ

What is the percentage of profitable transactions made by Kevin D. Freeman?
The percentage of profitable transactions made by Kevin D. Freeman is 40%.
What is the average return per transaction made by Kevin D. Freeman?
The average return per transaction made by Kevin D. Freeman is 5.80%.
What stocks does Kevin D. Freeman hold?
Kevin D. Freeman holds: GALT stocks.
What was Kevin D. Freeman’s latest transaction?
Kevin D. Freeman’s latest transaction was an Informative Buy of $19.47K.
What was Kevin D. Freeman's most profitable transaction?
Kevin D. Freeman’s most profitable transaction was an Informative Buy of GALT stock on December 26, 2024. The return on the trade was 365.50%.
What is Kevin D. Freeman's role in Galectin Therapeutics?
Kevin D. Freeman's role in Galectin Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.